Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | PTGIR | P43119 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710202 | 0.86 | ACHE (0.52) | ACHEHTR2CHTR1AHTR3ASMN1; SMN2 | |
| SCHEMBL9770219 | 0.85 | HTR2C (0.55) | ACHEHTR2CRELAPTGIRMTNR1A | |
| SCHEMBL11823658 | 0.82 | ALDH1A1 (0.54) | ACHEHTR2CPTGIRGAASMN1; SMN2 | |
| SCHEMBL31038384 | 0.82 | ACHE (0.48) | ACHEHTR2CHTR1AHTR3ASMN1; SMN2 | |
| SCHEMBL822376 | 0.82 | ACHE (0.48) | ACHEHTR2CHTR1AHTR3ASMN1; SMN2 | |
| SCHEMBL11125164 | 0.82 | ACHE (0.48) | ACHEHTR2CHTR1AHTR3ASMN1; SMN2 | |
| SCHEMBL29543680 | 0.82 | ACHE (0.58) | ACHEHTR2CHTR1AHTR3ATP53 | |
| SCHEMBL29468631 | 0.82 | ACHE (0.58) | ACHEHTR2CHTR1AHTR3ATP53 | |
| SCHEMBL575896 | 0.82 | ACHE (0.58) | ACHEHTR2CHTR1AHTR3ATP53 | |
| SCHEMBL31345530 | 0.81 | ACHE (0.53) | ACHEHTR2CRELAPTGIRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427536-B2 | Photocatalyst-free, light-induced carbon-sulfur cross-coupling methods | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-08-30 | — | — | US | disclosed |
| US-20180370911-A1 | PHOTOCATALYST-FREE, LIGHT-INDUCED CARBON-SULFUR CROSS-COUPLING METHODS | U.S. DEPARTMENT OF ENERGY | 2018-12-27 | — | — | US | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370911-A1 | PHOTOCATALYST-FREE, LIGHT-INDUCED CARBON-SULFUR CROSS-COUPLING METHODS | TST, CBS, CRY2 | ACHE 2054/4885HTR2C 724/4885RELA 306/4885 |
| US-11427536-B2 | Photocatalyst-free, light-induced carbon-sulfur cross-coupling methods | TST, CBS, CRY2 | ACHE 2054/4885HTR2C 724/4885RELA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.